Imara M&A

ELVN-002 Clinical Focus and Target Product Profile Our Opportunity ● Target Product Profile ● ● ● Drive Durable Responses ● Well Tolerated CNS activity Activity against: HER2 mutant NSCLC (e.g., Exon 20 IM) and Breast Cancer (e.g., L775) HER2 amplified and/or overexpressed tumors (breast, CRC, etc.) Brain metastases Selective: vs. wild-type EGFR Safety/tolerability: minimal Gl and skin toxicity (avoid EGFR-tox) Combinable: with SOC including ADCs across HER2-driven tumors Convenient: oral QD or BID | Dose Escalation in solid tumors with HER2 alterations ● ● Monotherapy in HER2-driven solid tumors Evaluate the safety in the combination with ADCs in HER2+ breast cancer and HER2 mutant NSCLC Expansion: 2L+ HER2 mutant NSCLC Single-arm study with potential to support accelerated approval Multiple Indication Opportunities • 1L HER2 mutant NSCLC +/- SOC Evaluate HER2+ CRC and HER2+ Breast in combination with SOC ● ADC = Antibody drug conjugate. BID = twice daily. CNS = Central nervous system. CRC = Colorectal cancer. Gl= Gastrointestinal. NSCLC = non-small cell lung cancer. SOC = Standard of care. TKI = Tyrosine kinase inhibitors. QD = once daily Explore other HER2 mutant solid tumors with "basket study" 36

View entire presentation